This observation may be of important clinical relevance, because HBXIP overexpression is frequently observed in tumor samples from NSCLC patients, and may confer tumor resistance to MEK inhibitors, which are broadly prescribed as clinical drugs to treat NSCLC. The gene discussed is MAP2K7; the disease is non-small cell lung carcinoma.